… 2.1 Study design, period, setting and population We conducted a cohort study to
determine BNT162b2 vaccine effectiveness in reducing infectivity. We reasoned that a …

… We conducted a cohort study to determine BNT162b2 vaccine effectiveness … reducing infectivity.
We reasoned that a … only after a period of 10 days following the first PCR, since repeated …

… by comparing infection risk between unvaccinated and fully-vaccinated (≥7 days … a low
incidence of SARS-CoV-2 infections in Israel following the high vaccine uptake of BNT162b2. …

… at least one dose of BNT162b2 with at least 14 days of follow-up after the first dose (ie, at
least partly … 14–21 days after the first dose of BNT162b2, albeit lower than that 6 days or fewer …

… study measuring the decrease rate of antibodies following administration of two doses of
BNT162b2 vaccine, or SARS-CoV-2 infection … -center, prospective, cross-sectional cohort study, …

… RNA load is lower in infected vaccinated persons compared … -2 infection by conducting a
prospective cohort study among … VE following two doses of Pfizer BNT162b2 mRNA vaccine …

… strain in Israel during the follow-up period and was likely the infecting VOC in most, if not
all, cases. The finding of a low VE against infection during follow-up is further supported by the …

… BNT162b2 vaccine starting a week after the second dose in a large-scale study performed in
Israel … However, our current study may suggest a lower protection against B.1.1.7 in the first …

… 2021, after having enrolled all institutions in Israel. Among … studies [2, 4, 5], we hypothesized
that the risk of SARS-CoV-2 infection 7 or 14 days following immunization will be lower …

… a reduced susceptibility in isolated contacts among vaccinated … assumed that vaccination
was effective from 7 days after the … impact of BNT162b2 vaccination on case infectivity and the …